Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

BACKGROUND: Anti-programmed cell death receptor-1 (PD-1) monotherapy is the standard treatment for metastatic melanoma in current. Camrelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody whose safety and efficacy have not been reported in advanced Asian melanoma patients. METHODS: This phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Li, Wu, Xiaowen, Chi, Zhihong, Si, Lu, Sheng, Xinan, Kong, Yan, Mao, Lili, Lian, Bin, Tang, Bixia, Yan, Xieqiao, Wang, Xuan, Bai, Xue, Li, Siming, Wei, Xiaoting, Li, Juan, Yang, Qing, Guo, Jun, Cui, Chuanliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123656/
https://www.ncbi.nlm.nih.gov/pubmed/35596181
http://dx.doi.org/10.1186/s12885-022-09663-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123656/
https://www.ncbi.nlm.nih.gov/pubmed/35596181
http://dx.doi.org/10.1186/s12885-022-09663-5

Ejemplares similares